Industry Partner News: Solid Biosciences' Letter to the Duchenne Community: Update on IGNITE DMD Clinical Trial

Dear Duchenne Community,

We were grateful for the opportunity to connect with so many Duchenne families at PPMD’s Annual Conference at the end of June in Orlando and have the chance to present an update on our IGNITE DMD clinical study. We would like to provide a further update to keep you all informed with the progress of the study.

Today, Solid announced that the second patient has been dosed in the higher dose cohort of the IGNITE DMD Phase I/II clinical trial of SGT-001, an AAV gene transfer candidate under investigation for Duchenne. As a reminder, this higher dose cohort is receiving a single administration of SGT-001 at 2E14 vg/kg, which is four times higher than our starting dose.

Solid has also made protocol amendments to the IGNITE DMD clinical study. One change includes adding an upper weight limit of 25 kg for at least the next patient dosed in the second cohort. Solid remains committed to dosing larger patients in the future. Another protocol amendment is the removal of the matched patient control arm for the rest of the second cohort. We believe these protocol changes will speed up the path to obtaining IGNITE DMD clinical trial results. As always, Solid understands the urgency in advancing meaningful therapies responsibly with the goal of impacting the broadest population of patients affected by Duchenne.

In other recent news, Solid announced in July that the company had raised $60 million in financing, strengthening our financial position.

Solid continues to anticipate providing a data update from the IGNITE DMD clinical trial later this year and we look forward to sharing all progress with the community.

Sincerely,

The Solid Biosciences Team

To read more about Solid Biosciences and their second quarter financial reporting, please click here.